Skip to content
Clinical Trials – home

Bon Secours Hospital Cork

Research site

Ireland College Road, T12 DV56 Cork, Ireland

  • 5 trials recruiting
  • Breast cancer · Fallopian tube cancer · Ovarian epithelial cancer
  • Adult patients

About Specializations

Bon Secours Hospital Cork in Cork, Ireland specialises in clinical trials of conditions such as Breast cancer, Fallopian tube cancer, Ovarian epithelial cancer, Embolism venous, and other specialisations. This site conducts important research.

Main research areas of the site

Breast Cancer and Early-Stage Oncology

At Bon Secours Hospital Cork, research in Medical Oncology focuses strongly on breast cancer, including metastatic breast cancer, triple negative breast cancer, and HR+/HER2-negative breast cancer. These studies are aimed at improving treatment effectiveness, refining adjuvant care, and testing whether new combinations can better prevent recurrence and extend survival.

  • Testing new treatment combinations for metastatic breast cancer
  • Evaluating therapy options for ER+/HER2-negative and hormone receptor-positive breast cancer
  • Studying strategies to reduce recurrence in early breast cancer

The site is also involved in research on whether treatment can be better tailored using risk markers, helping match therapy intensity more closely to each patient’s disease profile.

Gynecologic and Ovarian Cancers

Clinical trials at this hospital include a major emphasis on ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and related gynecologic malignancies. The research is designed to improve maintenance treatment, delay disease progression, and assess approaches that may reduce treatment-related side effects while preserving cancer control.

  • Maintenance treatment studies in platinum-sensitive ovarian cancer
  • Research in recurrent ovarian cancer with specific tumor markers
  • Evaluating safer and more effective options for advanced gynecologic cancers

This area reflects a broader effort to improve outcomes for women with hard-to-treat cancers by testing new therapies and supportive care approaches.

Prostate Cancer and Genitourinary Oncology

Another important focus is prostate cancer, including castration-resistant prostate cancer and localized very high-risk prostate cancer. Trials in this area are exploring ways to strengthen standard treatment, improve control of metastatic disease, and assess whether adding new therapies or radiation can better delay progression.

  • Studies for castration-resistant prostate cancer with limited metastatic disease
  • Research in localized very high-risk prostate cancer
  • Testing treatment combinations to improve progression-free survival

The research may be especially relevant for patients whose disease is identified through advanced imaging and for those needing more personalized treatment strategies.

Colorectal and Other Solid Tumors

The trial portfolio also includes colorectal cancer, along with other solid tumors such as stomach cancer and oesophageal cancer. These studies are focused on evaluating new therapy combinations, improving disease control after surgery, and testing treatments for cancers that have spread or are difficult to remove.

  • Research in unresectable or metastatic colorectal cancer
  • Studies addressing recurrence after treatment for common solid tumors
  • Exploring improved systemic treatment options for advanced gastrointestinal cancers

This work supports efforts to make treatment more effective across a range of gastrointestinal and solid tumor cancers.

Hematologic Malignancies and Blood Clot Prevention in Cancer

The site’s research also covers diffuse large B-cell lymphoma and cancer-associated venous thromboembolism, showing a broader interest in both cancer treatment and complication prevention. These trials aim to improve outcomes for people with blood cancers and to find better ways to prevent dangerous clotting events in patients with active cancer.

  • Evaluating new treatment options for relapsed or refractory DLBCL
  • Studying prevention of venous thromboembolism in patients with cancer
  • Comparing anticoagulation approaches to reduce clot recurrence

This combination of oncology and supportive care research highlights the site’s interest in both direct cancer control and safer long-term patient management.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
College RoadT12 DV56 CorkIreland
Recruiting now
5 trials
Conditions studied
22

More sites in CorkIreland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

22 clinical trials

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Prostate cancer

Not recruiting

Study on Darolutamide with Standard Therapy for Patients with High-Risk Localized Prostate Cancer

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Cancer Trials Ireland

Breast cancer

Not recruiting

Study on the Effects of Chemotherapy and Endocrine Therapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer Using Tamoxifen and Anastrozole

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Cancer Trials Ireland
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.